2,851
edits
Nicotinamide Mononucleotide (NMN): Difference between revisions
Nicotinamide Mononucleotide (NMN) (view source)
Revision as of 02:44, 16 November 2023
, 16 November 2023→Bioavailability of NMN
| Line 97: | Line 97: | ||
To address these challenges, various strategies and formulations have been developed: | To address these challenges, various strategies and formulations have been developed: | ||
* '''Liposomal Encapsulation''': Liposomal NMN involves wrapping NMN molecules in a lipid layer, which can help protect them from degradation in the digestive system and enhance absorption. | * '''[[Liposomes|Liposomal Encapsulation]]''': Liposomal NMN involves wrapping NMN molecules in a lipid layer, which can help protect them from degradation in the digestive system and enhance absorption. | ||
* '''Sublingual Administration''': Taking NMN sublingually (under the tongue) is proposed to increase its bioavailability by allowing direct absorption into the bloodstream, bypassing the digestive system. | * '''Sublingual Administration''': Taking NMN sublingually (under the tongue) is proposed to increase its bioavailability by allowing direct absorption into the bloodstream, bypassing the digestive system. | ||
* '''Microcrystalline Formulation''': MIB-626, a microcrystalline form of NMN developed by MetroBiotech, is believed to offer enhanced stability and bioavailability. | * '''Microcrystalline Formulation''': MIB-626, a microcrystalline form of NMN developed by MetroBiotech, is believed to offer enhanced stability and bioavailability. | ||